Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
Total Valuation
VYNE Therapeutics has a market cap or net worth of $27.68M. The enterprise value is $81.28M.
Market Cap$27.68M
Enterprise Value$81.28M
Share Statistics
VYNE Therapeutics has 15.21M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15.21M
Owned by Insiders11.01%
Owned by Instutions30.89%
Financial Efficiency
VYNE Therapeutics’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -83.63%.
Return on Equity (ROE)-76.48%
Return on Assets (ROA)-59.54%
Return on Invested Capital (ROIC)-83.63%
Return on Capital Employed (ROCE)-83.78%
Revenue Per Employee$38,538.462
Profits Per Employee-$3,062,692.308
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VYNE Therapeutics is -3.58. VYNE Therapeutics’s PEG ratio is 0.05.
PE Ratio-3.58
PS Ratio284.78
PB Ratio2.74
Price to Fair Value2.74
Price to FCF-4.19
Price to Operating Cash Flow-4.20
PEG Ratio0.05
Income Statement
In the last 12 months, VYNE Therapeutics had revenue of $501.00K and earned -$39.81M in profits. Earnings per share was -$0.94.
Revenue$501.00K
Gross Profit$501.00K
Operating Income-$43.64M
Pretax Income-$39.80M
Net Income-$39.81M
EBITDA-42.64M
Earnings Per Share (EPS)-0.94
Cash Flow
In the last 12 months, operating cash flow was -$33.97M and capital expenditures $0.00, giving a free cash flow of -$34.09M billion.
Operating Cash Flow-$33.97M
Free Cash Flow-$34.09M
Free Cash Flow per Share-$2.24
Dividends & Yields
VYNE Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-23.89%
Earnings Yield-27.92%
Stock Price Statistics
Beta1.40
52-Week Price Change-21.74%
50-Day Moving Average2.05
200-Day Moving Average2.28
Relative Strength Index (RSI)50.84
Average Volume (3m)175.31K
Important Dates
VYNE Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
VYNE Therapeutics as a current ratio of 4.35, with Debt / Equity ratio of <0.01
Current Ratio4.35
Quick Ratio4.35
Debt to Market Cap<0.01
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VYNE Therapeutics has paid $23.00K in taxes.
Income Tax$23.00K
Effective Tax Rate-0.01%
Enterprise Valuation
VYNE Therapeutics EV to EBITDA ratio is -2.82, with an EV/FCF ratio of -3.60.
EV to Sales245.20
EV to EBITDA-2.82
EV to Free Cash Flow-3.60
EV to Operating Cash Flow-3.62
Balance Sheet
VYNE Therapeutics has $61.52M in cash and marketable securities with $99.00K in debt, giving a net cash position of -$61.42M billion.
Cash & Marketable Securities$61.52M
Total Debt$99.00K
Net Cash-$61.42M
Net Cash Per Share-$4.04
Tangible Book Value Per Share$1.22
Margins
Gross margin is 100.00%, with operating margin of -8709.98%, and net profit margin of -7950.90%.
Gross Margin100.00%
Operating Margin-8709.98%
Pretax Margin-7944.71%
Net Profit Margin-7950.90%
EBITDA Margin-8709.18%
EBIT Margin-8709.98%
Analyst Forecast
The average price target for VYNE Therapeutics is $6.19, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.19
Price Target Upside243.89%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast18.16%
EPS Growth Forecast86.65%